Characteristics of Obstructive Sleep Apnea Syndrome Related Hypertension and the Effect of Continuous Positive Airway Pressure Treatment on Blood Pressure

March 28, 2022 updated by: ZiLi Meng, Huai'an No.1 People's Hospital

Huai'an First People's Hospital

Obstructive sleep apnea syndrome (OSAS) causes nocturnal chronic intermittent hypoxia (CIH) that contributes to the development of hypertension. CIH profiles, including the its length, speed and intensity were widely different in individuals. Until recently, the influence of OSAS-related IH profiles on hypertension development has not been fully explored. The present study aimed to investigate the effects of different CIH properties on blood pressure (BP) and short-term blood pressure variability (BPV) in severe OSAS patients.

Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. In theory, CPAP maintains upper airway patency and preserves ventilation, thereby inhibits the chain reaction over activation of the sympathetic nervous system and blood pressure regulating mechanism, thus CPAP treatment have adequate scientific basis to cause a substantial reduction arterial blood pressure, but controlled studies showed either no effect or only a minor decrease in arterial blood pressure by 1.4 and 2.5 mmHg respectively.The current, which type of combination of hypertension OSA patients can obtain the best antihypertensive benefit from CPAP therapy is still under debate.

Study Overview

Status

Completed

Detailed Description

Nocturnal BP was continuously monitored via measurement of pulse transmit time (PTT). The value of apnea-related systolic BP elevation (△BP) was used to reflect short-term BPV. Beat-to-beat RR interval data were incorporated in polysomnography for heart rate variability analysis. LF/HF band ratio was compared between two groups which used to reflect sympatho-vagal balance. The length of the desaturation event was measured to the nearest 0.5 second (△t). The fall in SpO2 during apnea was calculated as the gap from start of the desaturation to the nadir of the desaturation. The rate of fall in SpO2 was counted as the change in the percentage of SpO2 per second (△SpO2 /△t) and expressed as oxygen desaturation rate (ODR), which reflected the speed and efficacy of oxygen desaturation during an apnea event. One hundred and two severe OSAS subjects were divided into two groups according to the their median ODR: faster ODR and slower ODR.

In addtion,patient were categorized into three groups: Group l: systolic blood pressure index was less than 30% of AHI; Group 2: systolic blood pressure index was less than 60% but more than 30%; Group 3: systolic blood pressure index is more than 60% of AHI. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated. The main purpose of study is to confirm the OSA with hypertension and OSA secondary hypertension are two different concepts. Basis for the clinical treatment, the former, CPAP might have no effect or only a minor decrease in arterial blood pressure, while the latter CPAP treatment might achieve significant antihypertensive effect.

Study Type

Observational

Enrollment (Actual)

78

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Jiangsu
      • Huai'an, Jiangsu, China, 223300
        • Department Of Respiratory Medicine,Huai'an First People's Hospital,Nanjing Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

  1. age between 18 to 70 yrs;
  2. newly diagnosed OSAS without treatment;

Description

Inclusion Criteria:

  1. BP≤180/110mmHg,but≥140/90mmHg
  2. without taking oral antihypertensive drugs. Exclusion criteria.

(1) patients who had been hospitalized for cardiac or respiratory exacerbation<6wk prior to recruiting; (2) with autonomic nervous system diseases or endocrine disorders which might influence BP; (3) unwilling to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group l
SBP index was less than 30% of AHI
Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
Group 2
SBP index was less than 60% but more than 30%
Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
awake systolic blood pressure(SBP)changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
as the mean systolic blood pressure measurements during a supine resting period of 1 0minute at awake state
change from Baseline Systolic Blood Pressure at 2 weeks
sleep systolic blood pressure(SBP)changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
as the average of systolic blood pressure values during sleep
change from Baseline Systolic Blood Pressure at 2 weeks
sympathetic-parasympathetic nerve balance changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
Studies using spectral analysis of R-R intervals have reported that the power spectrum contains both low-frequency(LF,0.04-0.15 Hz)and high-frequency peaks(HF,0.15-0.5Hz),HF power reflects parasympathetic activity,whereas LF power primarily reflects sympathetic activity with a parasympathetic component.The LF-to-HF ratio(LF/HF)is commonly regarded as an index of sympathovagal balance
change from Baseline Systolic Blood Pressure at 2 weeks
renin-angiotensin-aldosterone systemchanges
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
as the levels of plasma angiotension ⅰ( Ang I) and angiotension ⅱ( Ang ⅱ) before and after CPAP treatment
change from Baseline Systolic Blood Pressure at 2 weeks
AHI changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
the combined number of apnea and hypopnea episodes per hour of sleep
change from Baseline Systolic Blood Pressure at 2 weeks
TST90 changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
percentage of sleep time with oxygen saturation < 90%
change from Baseline Systolic Blood Pressure at 2 weeks
oxygen desaturation index(ODI) changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
oxygen desaturation index
change from Baseline Systolic Blood Pressure at 2 weeks
event-related systolic blood pressure elevation (△SBP) changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
as the gap between the peak value of postapneic SBP and lowest SBP during a obstructive respiratory event
change from Baseline Systolic Blood Pressure at 2 weeks
systolic blood pressure(SBP)index
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
as the number of △SBP>10mmHg per hour of sleep time.
change from Baseline Systolic Blood Pressure at 2 weeks
Desaturation rate
Time Frame: one night
The rate of fall in SpO2 was counted as the change in the percentage of SpO2 per second during apnea
one night

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Zili Meng, Master, Department Of Respiratory Medicine,Huai'an First People's Hospital,Nanjing Medical University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 3, 2018

Primary Completion (Actual)

December 30, 2021

Study Completion (Actual)

December 30, 2021

Study Registration Dates

First Submitted

August 5, 2017

First Submitted That Met QC Criteria

August 9, 2017

First Posted (Actual)

August 11, 2017

Study Record Updates

Last Update Posted (Actual)

March 29, 2022

Last Update Submitted That Met QC Criteria

March 28, 2022

Last Verified

August 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension Secondary

Clinical Trials on continuous positive airway pressure

3
Subscribe